Perceptive Advisors LLC bought $2.3M of VRCA
owner at Verrica Pharmaceuticals Inc.. 321,616 shares at an average of $7.17, traded Dec 27, 2023, filed Dec 29, 2023.
Score components
- +12Role10% owner
- +25Trade size$2.3M at market
- 0Relative to holdingsHoldings up 4.7%
- +4Price context16% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (2 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -20.9%, 3m -19.1%, 6m -0.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001062993-23-023292, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 27, 2023 | POpen-market purchase Common Stockindirect: See Footnote | +79,726 | $7.20 | $574k | 6,857,292 | Dec 29, 2023 |
| Dec 28, 2023 | POpen-market purchase Common Stockindirect: See Footnote | +126,116 | $7.08 | $893k | 6,983,408 | Dec 29, 2023 |
| Dec 29, 2023 | POpen-market purchase Common Stockindirect: See Footnote | +115,774 | $7.24 | $838k | 7,099,182 | Dec 29, 2023 |
Related signals
Other insiders at Verrica Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 51Moderate | Verrica Pharmaceuticals Inc. | John J. Kirby Interim CFO | $25k 5,000 shares | +26% | |
| 62Notable | Verrica Pharmaceuticals Inc. | Jayson Rieger CEO and President | $126k 25,000 shares | +14% | |
| 53Moderate | Verrica Pharmaceuticals Inc. | Noah L. Rosenberg CMO | $31k 6,230 shares | +264% | |
| 54Moderate | Verrica Pharmaceuticals Inc. | David Zawitz Chief Operating Officer | $30k 6,000 shares | +29% | |
| 55Moderate | Verrica Pharmaceuticals Inc. | John J. Kirby Interim CFO | $15k 3,536 shares | +65% | |
| 73Notable | Verrica Pharmaceuticals Inc. | Paul B Manning director, owner | $18M 4,126,142 shares | +160% | |
| 74Notable | Verrica Pharmaceuticals Inc. | Jayson Rieger CEO and President | $400k 94,311 shares | +107% | |
| 46Moderate | Verrica Pharmaceuticals Inc. | Noah L. Rosenberg CMO | $10,000 2,357 shares | - | |
| 59Moderate | Verrica Pharmaceuticals Inc. | David Zawitz Chief Operating Officer | $42k 10,000 shares | +91% | |
| 15Weak | VRCAsell Verrica Pharmaceuticals Inc. | Christopher G. Hayes CHIEF LEGAL OFFICER | $2,805 4,315 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.